A Phase I, Open label, Multi-Center Clinical Pharmacological Study of nemolizumab with a Single-dose in Japanese Atopic Dermatitis Patients with moderate to severe pruritus
Phase 1
Completed
- Conditions
- Atopic dermatitis with pruritus who are inadequately controlled by existing therapies
- Registration Number
- JPRN-jRCT2080225290
- Lead Sponsor
- Maruho Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Atopic dermatitis with moderate or severe pururitus Patients
Exclusion Criteria
-Patients with Hepatitis B virus or hepatitis C virus infection
-Patients with Evidence of tuberculosis (TB) infection
-Patients with immune deficiency
-Pregnant or lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method